Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Sales (2018 - 2025)

Historic Return on Sales for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 0.28%.

  • BioNexus Gene Lab's Return on Sales rose 2300.0% to 0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.17% for FY2024, which is 1000.0% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Return on Sales is 0.28%, which was up 2300.0% from 0.27% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Return on Sales registered a high of 0.21% during Q4 2021, and its lowest value of 1.02% during Q3 2023.
  • For the 5-year period, BioNexus Gene Lab's Return on Sales averaged around 0.11%, with its median value being 0.03% (2024).
  • In the last 5 years, BioNexus Gene Lab's Return on Sales plummeted by -9900bps in 2023 and then soared by 5100bps in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Return on Sales stood at 0.21% in 2021, then plummeted by -109bps to 0.02% in 2022, then surged by 939bps to 0.15% in 2023, then crashed by -187bps to 0.14% in 2024, then plummeted by -106bps to 0.28% in 2025.
  • Its Return on Sales stands at 0.28% for Q3 2025, versus 0.27% for Q2 2025 and 0.29% for Q1 2025.